- Home
- BCRX vs TARS Comparison
BCRX vs TARS Comparison
Compare BCRX & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BCRX | TARS |
|---|---|---|
| Founded | 1986 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 3.4B |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BCRX | TARS |
|---|---|---|
| Price | $7.54 | $74.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 10 |
| Target Price | $20.45 | ★ $103.44 |
| AVG Volume (30 Days) | ★ 5.5M | 875.2K |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 381.40 | 48.21 |
| EPS | ★ N/A | N/A |
| Revenue | $25,186,000.00 | ★ $451,360,000.00 |
| Revenue This Year | N/A | $63.81 |
| Revenue Next Year | $3.71 | $24.45 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 146.71 |
| 52 Week Low | $6.23 | $53.89 |
| 52 Week High | $11.22 | $91.53 |
Technical Indicators
Market Signals| Indicator | BCRX | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 40.62 | 55.08 |
| Support Level | $6.23 | $68.56 |
| Resistance Level | $10.05 | $76.79 |
| Average True Range (ATR) | 0.38 | 3.84 |
| MACD | -0.04 | 0.20 |
| Stochastic Oscillator | 13.87 | 79.89 |
Price Performance
Historical ComparisonAbout BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.